From Baron Funds' second quarter commentary:
Grifols SA (GRFS, Financial) manufactures and sells plasma derivative healthcare products to hospitals and physicians globally. Grifols' NASDAQ-traded ADR increased over 24% during the quarter. Grifols' plasma proteins are an essential medical treatment for patients with primary immune deficiency, neurological diseases or hemophilia. Few companies can manufacture these treatments with a high degree of quality and consistency. Healthy demand for the product, coupled with a strong pricing environment, helped Grifols during the quarter.We continue to believe that Grifols will generate strong synergies from its 2011 acquisition of U.S.-based Talecris, and that Grifols will become significantly more profitable going forward. (Aaron Wasserman)
Grifols SA (GRFS, Financial) manufactures and sells plasma derivative healthcare products to hospitals and physicians globally. Grifols' NASDAQ-traded ADR increased over 24% during the quarter. Grifols' plasma proteins are an essential medical treatment for patients with primary immune deficiency, neurological diseases or hemophilia. Few companies can manufacture these treatments with a high degree of quality and consistency. Healthy demand for the product, coupled with a strong pricing environment, helped Grifols during the quarter.We continue to believe that Grifols will generate strong synergies from its 2011 acquisition of U.S.-based Talecris, and that Grifols will become significantly more profitable going forward. (Aaron Wasserman)
